What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no approved disease‐modifying therapy (DMT). In this review, we summarize the various past approaches taken in an attempt to find treatments capable of altering the long‐term course for individuals with AD, including: translating epidemiological observations into potential treatment options; seeking a single‐treatment approach across the continuum of AD severity; utilizing biomarkers for assessing target engagement; using biomarkers as early surrogates of clinical efficacy; and enriching study populations to demonstrate adequate placebo decline during the limited duration of clinical trials. Although targeting the amyloid‐β (Aβ) pathway has been central to the search for an effective DMT, to date, trials of anti‐Aβ monoclonal antibodies have failed to consistently demonstrate significant clinical efficacy. Key learnings from these anti‐Aβ trials, as well as the trials that came before them, have shifted the focus within clinical development programs to identifying target populations thought most likely to benefit from treatments (i.e., individuals at an earlier stage of disease). Other learnings include strategies to increase the likelihood of showing measurable improvements within the clinical trial setting by better predicting decline in placebo participants, as well as developing measures to quantify the needed treatment exposure (e.g., higher doses). Given the complexity associated with AD pathology and progression, treatments targeting non‐amyloid AD pathologies in combination with anti‐amyloid therapies may offer an alternative for the successful development of DMTs. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 4×
“Analyses of the NTB domain scores demonstrated improvement in executive functioning (83% higher) and processing speed (150% higher) in the intervention versus control groups (Ngandu et al., 2015).”
InfluentialThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 4×
“ARIA incidence for these N-terminus anti-amy-loid antibodies increased in a dose-dependent and APOE ε 4-de-pendent manner (Ostrowitzki et al., 2017; Salloway et al., 2014; Sevigny et al., 2016).”
InfluentialTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 6×
“Anti-A β monoclonal antibodies, including bapineu-zumab (Rinne et al., 2010; Salloway et al., 2009, 2014), solanezumab (Doody et al., 2014; Farlow et al., 2012; Honig et al., 2018; Siemers et al., 2010), aducanumab (Biogen, 2019; ClinicalTrials.gov, 2019q [NCT02477800]; Sevigny et al., 2016;…”
InfluentialMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 3×
“Although the biomarker data in phase II demonstrated dose-dependent changes, in phase III testing, there was no significant change on several clinical outcomes, including ADAS-Cog11, ADCS-ADL, CDR-SB, NPI, and MMSE, following treatment with solanezumab (Doody et al., 2014).”
InfluentialSelf-citationLarson, E. B., Wang, L., Bowen, J. D., McCormick, W. C., Teri, L., Crane, P., & Kukull, W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00004 · Cited by 1,463
Williamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246 · cited 1×
“…2010; Harrington et al., 2011; Kwok et al., 2011; Reines et al., 2004; van Rossum et al., 2012; Sano et al., 2011; SPRINT MIND Investigators for the SPRINT Research Group et al., 2019; Stein, Scherer, Ladd, & Harrison, 2011; Sun, Lu, Chien, Chen, & Chen, 2007; Van Gool, Weinstein, Scheltens, &…”
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationThe worldwide costs of dementia 2015 and comparisons with 2010
Wimo, A., Guerchet, M., Ali, G., Wu, Y., Prina, A. M., Winblad, B., Jönsson, L., Liu, Z., & Prince, M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.150 · Cited by 1,066 · cited 1×
“Globally, the economic cost of dementia was estimated to be $818 billion in 2015, a 35.4% increase in cost compared with the $604 billion estimate from 2010 (Wimo et al., 2017).”
InfluentialTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“…antibodies, including bapineu-zumab (Rinne et al., 2010; Salloway et al., 2009, 2014), solanezumab (Doody et al., 2014; Farlow et al., 2012; Honig et al., 2018; Siemers et al., 2010), aducanumab (Biogen, 2019; ClinicalTrials.gov, 2019q [NCT02477800]; Sevigny et al., 2016;…”
Cited by
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Dominguez, L., Shea, J.-E., Dokholyan, N. V., De Simone, A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 678
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
The Microbiome as a Modifier of Neurodegenerative Disease Risk
Fang, P., Kazmi, S. A., Jameson, K. G., & Hsiao, E. Y. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.008 · Cited by 226
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
“The well-documented struggles of clinical trials to demonstrate significant cognitive benefits of disease-modifying therapies targeting amyloid beta (A β ) 7,8 despite the substantial body of evidence supporting its toxic role emphasize several major problems.”
Perspectives and challenges in patient stratification in Alzheimer’s disease
Abdelnour, C., Agosta, F., Bozzali, M., Fougère, B., Iwata, A., Nilforooshan, R., Takada, L. T., Viñuela, F., & Traber, M. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01055-y · Cited by 108
“Patient stratification to enrich clinical trial populations A challenge for clinical trials is identifying people with AD who are likely to progress rapidly, as they are more likely to indicate whether a new drug is efficacious over the duration of a late phase clinical trial [40].”
BackgroundMethodInfluential
Metadata
- Authors
- Bullain, S., & Doody, R.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2020-05-09
- Volume
- 155
- Issue
- 2
- Pages
- 120-136
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W3015590050
- Cited by
- 38
- References
- 38
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. https://app.cochat.ai/papers/10.1111/jnc.15023
- The paper
- Bullain, S., & Doody, R. (2020). What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. Journal of Neurochemistry. https://doi.org/10.1111/jnc.15023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.